Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 15/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12628022 | 1.00 | RBP4 (0.43) | RBP4GSK3BLRRK2CFTRPDK1 | |
| SCHEMBL1176036 | 1.00 | RBP4 (0.43) | RBP4GSK3BLRRK2CFTRPDK1 | |
| Formic Acid SCHEMBL5557691 | 0.96 | RBP4 (0.41) | RBP4GSK3BLRRK2CFTRPDK1 | |
| SCHEMBL5046515 | 0.92 | TRPA1 (0.39) | RBP4GSK3BCFTR | |
| SCHEMBL1176642 | 0.92 | TRPA1 (0.39) | RBP4GSK3BCFTR | |
| SCHEMBL1176146 | 0.89 | GSK3B (0.46) | RBP4GSK3BLRRK2DYRK1A | |
| SCHEMBL5048308 | 0.89 | GSK3B (0.46) | RBP4GSK3BLRRK2DYRK1A | |
| Formic Acid SCHEMBL5556201 | 0.89 | TRPA1 (0.36) | RBP4GSK3BLRRK2CFTR | |
| SCHEMBL5044513 | 0.88 | GSK3B (0.52) | RBP4GSK3BDYRK1A | |
| SCHEMBL1175931 | 0.88 | GSK3B (0.52) | RBP4GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304297-A1 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET | ALLERGAN SALES, LLC (US) | 2017-10-26 | — | — | US | claimed |
| US-20150224097-A1 | Immediate Release Abuse Deterrent Tablet | WATSON PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | claimed |
| EP-2782558-A1 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET | Watson Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | claimed |
| WO-2013077851-A1 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET | WATSON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | claimed |
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| US-11992468-B2 | Abuse-deterrent dosage forms containing esketamine | CLEXIO BIOSCIENCES LTD. (IL) | 2024-05-28 | — | — | US | disclosed |
| US-11844796-B2 | Immediate release abuse-deterrent granulated dosage forms | CLEXIO BIOSCIENCES LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| US-20230364108-A1 | NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT | FATHOLAHI SHAHIN (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230301941-A1 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | CLEXIO BIOSCIENCES LTD. (IL) | 2023-09-28 | — | — | US | disclosed |
| US-20230293445-A1 | IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS | CLEXIO BIOSCIENCES LTD (IL) | 2023-09-21 | — | — | US | disclosed |
| US-11730702-B2 | Immediate release abuse-deterrent granulated dosage forms | CLEXIO BIOSCIENCES, LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| US-11534409-B2 | Immediate release abuse-deterrent granulated dosage forms | CLEXIO BIOSCIENCES LTD. (IL) | 2022-12-27 | — | — | US | disclosed |
| US-20150118303-A1 | Immediate Release Abuse-Deterrent Granulated Dosage Forms | CLEXIO BIOSCIENCES LTD. (IL) | 2015-04-30 | — | — | US | disclosed |
| EP-2782558-A1 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET | Watson Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013077851-A1 | IMMEDIATE RELEASE ABUSE DETERRENT TABLET | WATSON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-02-03 | — | — | US | disclosed |
| EP-1912631-A2 | DILTIAZEM CONTROLLED RELEASE FORMULATION AND METHOD OF MANUFACTURE | Watson Pharmaceuticals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021754-A2 | DILTIAZEM CONTROLLED RELEASE FORMULATION AND METHOD OF MANUFACTURE | WATSON PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070036856-A1 | Diltiazem controlled release formulation and method of manufacture | ANDRX LABS LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301941-A1 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | OPRK1, KHK, BCKDK | RBP4 2012/4885GSK3B 4447/4885LRRK2 2909/4885 |
| US-11992468-B2 | Abuse-deterrent dosage forms containing esketamine | OPRK1, KHK, BCKDK | RBP4 2012/4885GSK3B 4447/4885LRRK2 2909/4885 |
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | RBP4 4283/4885GSK3B 608/4885LRRK2 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.